C Van de Wiele, V Cocquyt, R VandenBroecke, F De Vos, S Van Belle, K Dhaene, G Slegers, R A Dierckx
UNLABELLED: Assessing tumor uptake and retention of (123)I-labeled tamoxifen (TX) could increase our understanding of TX's action and the mechanisms involved in resistance to the drug.METHODS: Nine untreated primary breast carcinoma patients underwent whole-body planar and tomographic (SPECT) imaging 30 min and 4-5 h after injection of 185 MBq (123)I-TX. Tumor-to-normal tissue uptake ratios (T/N) derived from SPECT images were related to estrogen receptor (ER) and progesterone receptor (PR) status.RESULTS: In 4 of 9 patients, all of whom were ER+/PR+, (123)I-TX tumor uptake was clearly depicted. In 2 of them, involved axillary lymph nodes were also visualized. T/N consistently increased over time. All ER+/PR- and ER-/PR- tumors as well as 2 ER+/PR+ tumors were (123)I-TX-.CONCLUSION: These preliminary findings suggest that (123)I-TX is preferentially taken up in alpha-ER+/PR+ breast tumors known to be more likely to respond to endocrine treatment.
Van de Wiele, C, Cocquyt, V, VandenBroecke, R, De Vos, F, Van Belle, S, Dhaene, K, Slegers, G & Dierckx, RA 2001, 'Iodine-labeled tamoxifen uptake in primary human breast carcinoma', Journal of Nuclear Medicine, vol. 42, no. 12, pp. 1818-1820.
Van de Wiele, C., Cocquyt, V., VandenBroecke, R., De Vos, F., Van Belle, S., Dhaene, K., Slegers, G., & Dierckx, R. A. (2001). Iodine-labeled tamoxifen uptake in primary human breast carcinoma. Journal of Nuclear Medicine, 42(12), 1818-1820.
@article{ead4f4b672874d0cab78a29c4d85205f,
title = "Iodine-labeled tamoxifen uptake in primary human breast carcinoma",
abstract = "UNLABELLED: Assessing tumor uptake and retention of (123)I-labeled tamoxifen (TX) could increase our understanding of TX's action and the mechanisms involved in resistance to the drug.METHODS: Nine untreated primary breast carcinoma patients underwent whole-body planar and tomographic (SPECT) imaging 30 min and 4-5 h after injection of 185 MBq (123)I-TX. Tumor-to-normal tissue uptake ratios (T/N) derived from SPECT images were related to estrogen receptor (ER) and progesterone receptor (PR) status.RESULTS: In 4 of 9 patients, all of whom were ER+/PR+, (123)I-TX tumor uptake was clearly depicted. In 2 of them, involved axillary lymph nodes were also visualized. T/N consistently increased over time. All ER+/PR- and ER-/PR- tumors as well as 2 ER+/PR+ tumors were (123)I-TX-.CONCLUSION: These preliminary findings suggest that (123)I-TX is preferentially taken up in alpha-ER+/PR+ breast tumors known to be more likely to respond to endocrine treatment.",
keywords = "Breast Neoplasms/diagnostic imaging, Carcinoma, Ductal, Breast/diagnostic imaging, Carcinoma, Lobular/diagnostic imaging, Feasibility Studies, Female, Humans, Immunohistochemistry, Iodine Radioisotopes, Receptors, Estrogen/metabolism, Receptors, Progesterone/metabolism, Tamoxifen/pharmacokinetics, Tomography, Emission-Computed, Single-Photon",
author = "{Van de Wiele}, C and V Cocquyt and R VandenBroecke and {De Vos}, F and {Van Belle}, S and K Dhaene and G Slegers and Dierckx, {R A}",
year = "2001",
month = dec,
language = "English",
volume = "42",
pages = "1818--1820",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "12",
}